International AIDS Vaccine Initiative & Gilead Sciences

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing rVSV Bundibugyo, a single-dose vaccine candidate seen as promising by the World Health Organization, though it is not yet ready for trials.

Gilead Sciences: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is working on a modified version of the Zaire Ebola vaccine to fight the Bundibugyo strain, with experimental jabs showing nearly 100% protection in monkeys.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.